Drug Development Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK.
EPMA J. 2012 Jan 12;3(1):3. doi: 10.1007/s13167-011-0138-2.
Prostate cancer remains the most common malignancy among men and the second leading cause of male cancer-related mortality. Death from this disease is invariably due to resistance to androgen deprivation therapy. Our improved understanding of the biology of prostate cancer has heralded a new era in molecular anticancer drug development, with multiple novel anticancer drugs for castration resistant prostate cancer now entering the clinic. These include the taxane cabazitaxel, the vaccine sipuleucel-T, the CYP17 inhibitor abiraterone, the novel androgen receptor antagonist MDV-3100 and the radionuclide alpharadin. The management and therapeutic landscape of prostate cancer has now been transformed with this growing armamentarium of effective antitumor agents. This review discusses strategies for the prevention and personalization of prostate cancer therapy, with a focus on the development of predictive and intermediate endpoint biomarkers, as well as novel clinical trial designs that will be crucial for the optimal development of such anticancer therapeutics.
前列腺癌仍然是男性中最常见的恶性肿瘤，也是男性癌症相关死亡的第二大主要原因。死于这种疾病的人无一例外地是由于对雄激素剥夺疗法的耐药性。我们对前列腺癌生物学的认识的提高预示着分子抗癌药物开发的新时代已经到来，目前有多种新型抗癌药物用于去势抵抗性前列腺癌，现已进入临床阶段。这些药物包括紫杉醇类药物卡巴他赛、疫苗 sipuleucel-T、CYP17 抑制剂阿比特龙、新型雄激素受体拮抗剂 MDV-3100 和放射性核素阿尔法粒子。随着这些有效的抗肿瘤药物的不断涌现，前列腺癌的治疗和管理格局已经发生了变化。本文讨论了前列腺癌预防和个体化治疗的策略，重点是预测和中间终点生物标志物的开发，以及新的临床试验设计，这些对于这种抗癌治疗的最佳开发至关重要。
